iBio rises as obesity drug gets nod for human trial in Australia

ReutersApr 8, 2026 3:16 PM

Shares of iBio IBIO.O rise nearly 5% to $2.21

Biotech firm says Australian regulators have cleared first human study of its experimental obesity drug IBIO-600

Drug targets obesity and aims to preserve muscle while people lose weight - IBIO

Says IBIO-600 is designed to be used alongside GLP-1 weight-loss drugs, which can cause muscle loss

Adds that early-stage study will test safety and how the drug behaves in overweight and obese adults

Animal studies showed gains in lean muscle and reductions in fat; drug could be dosed just a few times a year - IBIO

Including session's move, stock up about 15% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Michael Burry says Anthropic is 'Eating Palantir's Lunch', is Palantir Still a buy?

TradingKey - PLTR drops over 7% on Burry's Anthropic enterprise data. Maven Program of Record, $142x valuation risk, and $125 support level analysed.

Anthropic Claude Mythos Preview Sparks Wall Street Panic: Bessent, Powell Summon CEOs; Cloudflare Tumbles 8%

TradingKey - According to the latest Bloomberg report, U.S. Treasury Secretary Bessent and Federal Reserve Chair Jerome Powell urgently convened a meeting with the CEOs of major Wall Street banks this Tuesday to discuss potential cybersecurity threats posed by Anthropic's latest AI model, Mythos. Th

SpaceX Eyes IPO Amid Exposed $5B Loss: Will xAI 'Burn Rate' Drag Down $2T Valuation?

TradingKey - The Information reports that SpaceX's 2025 revenue exceeded $18.5 billion, while net losses approached $5 billion. Analysis suggests these figures reflect the drag on SpaceX following its merger with xAI. Influenced by xAI, will SpaceX's target IPO valuation be significantly discounted?

Nvidia Rises for Seven Straight Days, AI Chip Leader’s Stock May Break All-Time High

TradingKey - On Thursday (April 10), Nvidia shares closed approximately 1% higher at $183.94, marking its seventh consecutive session of gains and its longest winning streak since November 2023. While the magnitude of this rally is not particularly dramatic, its significance lies in the market’s renewed willingness to buy into Nvidia's AI growth story following months of repeated volatility.

From 14.2 Billion to 21 Billion, Why Meta Continues to Bet on CoreWeave?

TradingKey - On April 9, AI cloud computing provider CoreWeave (CRWV) announced a long-term partnership agreement valued at $21 billion with Meta (META). The company will provide Meta with dedicated AI cloud computing capacity, with the service term extending through December 2032.

Featured Tools